Product Image

Contributor Information

  • Institute Northern Institute For Cancer Research, Newcastle University

Tool Details

  • Tool name: LNCaP: ARW741L cell line
  • Alternate names: AR, Dihydrotestosterone Receptor, Nuclear Receptor Subfamily 3 Group C Member 4, NR3C4, DHTR
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: LNCaP
  • Organism: Human
  • Cancer type: Human prostate adenocarcinoma
  • Disease: Cancer
  • Description: LNCaP cells are androgen-sensitive human prostate adenocarcinoma cells derived from the left supraclavicular lymph node metastasis from a 50-year-old Caucasian male in 1977. The androgen receptor (AR) in LNCaP cells harbours a T877A mutations which enables the anti-androgen flutamide to act as an agonist. This cell line is the most commonly used for prostate cancer research. In approximately 30% CRPC, AR mutations are detected and are likely selected for under pressure by hormonal therapies.Mutations within the AR ligand-binding domain, the site of testosterone and anti-androgen binding, enable retention of AR signalling in the presence of hormonal therapies. Two AR LBD mutations are commonly detected in patients treated with bicalutamide and enzalutamide, W741L and F876L, respectively. These convert the activity of anti-androgens from antagonists to agonists and enable progression of CRPC. Modelling these mutations previously has been difficult and have been limited to, principally, luciferase-based assays in non-AR-expressing cell lines. We have therefore developed two key LNCaP cell derivatives that have stable expression of ARW741L and ARF876L (Cat No:154163) mutations which enables us to assess the activity of these aberrantly functioning receptors in a physiological background. Moreover, by depleting endogenous AR in LNCaP cells, we can provide a clean read-out for mutant AR activity that can be utilised for assessing efficacy of novel AR-targeting agents
  • Research area: Cancer

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Growth medium: RPMI-1640 + 10% FBS
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   O'Neill et al. 2015. Oncotarget. 6(28):26029-40. PMID: 26267320.
  •   Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.